These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36249705)

  • 1. A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy.
    Khanani AM; Maturi RK; Bagheri N; Bakall B; Boyer DS; Couvillion SS; Dhoot DS; Holekamp NM; Jamal KN; Marcus DM; Pieramici D; Aziz AA; Patki KC; Bridges WZ; Barone SB
    Ophthalmol Sci; 2022 Jun; 2(2):100154. PubMed ID: 36249705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.
    Mettu PS; Allingham MJ; Cousins SW
    Ophthalmol Sci; 2022 Mar; 2(1):100086. PubMed ID: 36246181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.
    Allingham MJ; Mettu PS; Cousins SW
    Ophthalmol Sci; 2022 Mar; 2(1):100095. PubMed ID: 36246187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results.
    Wykoff CC; Hershberger V; Eichenbaum D; Henry E; Younis HS; Chandra P; Yuan N; Solloway M; DePaoli A
    Am J Ophthalmol; 2022 Mar; 235():131-142. PubMed ID: 34509438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular Degeneration.
    Kato Y; Oguchi Y; Omori T; Kasai A; Ogasawara M; Sugano Y; Itagaki K; Ojima A; Ishida Y; Machida T; Sekine H; Sekiryu T
    Ophthalmol Sci; 2022 Jun; 2(2):100167. PubMed ID: 36249678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar
    Biggs RM; Makou E; Lauder S; Herbert AP; Barlow PN; Katti SK
    Curr Eye Res; 2022 Jul; 47(7):1087-1093. PubMed ID: 35282732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD.
    Wells JA; Gonzales CR; Berger BB; Gonzalez VH; Sippy BD; Burian G
    Ophthalmic Surg Lasers Imaging Retina; 2018 May; 49(5):336-345. PubMed ID: 29772044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
    Nguyen QD; Shah SM; Browning DJ; Hudson H; Sonkin P; Hariprasad SM; Kaiser P; Slakter JS; Haller J; Do DV; Mieler WF; Chu K; Yang K; Ingerman A; Vitti RL; Berliner AJ; Cedarbaum JM; Campochiaro PA
    Ophthalmology; 2009 Nov; 116(11):2141-8.e1. PubMed ID: 19700196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study.
    Heier JS; Ho AC; Samuel MA; Chang T; Riemann CD; Kitchens JW; Slakter JS; Leiderman YI; Spencer R; Williams GA; Hickson-Curran SB; Keane M; Baldassarre JS;
    Ophthalmol Retina; 2020 Apr; 4(4):384-393. PubMed ID: 32033908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Maguire MG; Ying GS; Jaffe GJ; Toth CA; Daniel E; Grunwald J; Martin DF; Hagstrom SA;
    JAMA Ophthalmol; 2016 Jun; 134(6):674-81. PubMed ID: 27099955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
    Khanani AM; Hershberger VS; Pieramici DJ; Khurana RN; Brunstein F; Ma L; Maass KF; Honigberg LA; Tom I; Chen H; Strauss EC; Lai P;
    Am J Ophthalmol; 2021 Dec; 232():49-57. PubMed ID: 34214452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.
    Petrou PA; Cunningham D; Shimel K; Harrington M; Hammel K; Cukras CA; Ferris FL; Chew EY; Wong WT
    Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):330-8. PubMed ID: 25525171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Jaffe GJ; Eliott D; Wells JA; Prenner JL; Papp A; Patel S
    Ophthalmology; 2016 Jan; 123(1):78-85. PubMed ID: 26499921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
    Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
    Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.
    Zhang M; Zhang J; Yan M; Luo D; Zhu W; Kaiser PK; Yu DC;
    Ophthalmology; 2011 Apr; 118(4):672-8. PubMed ID: 21146224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.
    Kaiser PK; Symons RC; Shah SM; Quinlan EJ; Tabandeh H; Do DV; Reisen G; Lockridge JA; Short B; Guerciolini R; Nguyen QD;
    Am J Ophthalmol; 2010 Jul; 150(1):33-39.e2. PubMed ID: 20609706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Abdelfattah NS; Lei J; Shi Y; Marion KM; Morgenthien E; Gune S; Balasubramanian S
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
    Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.